Header Logo

Connection

WENDY KEITEL to Influenza Vaccines

Back to Details
This is a "connection" page, showing publications WENDY KEITEL has written about Influenza Vaccines.
WENDY KEITEL
Connection Strength
11.991
Influenza Vaccines
  1. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
    View in: PubMed
    Score: 0.596
  2. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.544
  3. Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020 07 14; 38(33):5355-5363.
    View in: PubMed
    Score: 0.493
  4. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
    View in: PubMed
    Score: 0.489
  5. Searching for Improved Flu Vaccines-The Time Is Now. J Infect Dis. 2020 01 01; 221(1):1-4.
    View in: PubMed
    Score: 0.477
  6. Influenza Vaccines After 7 Decades: Still on the Learning Curve. J Infect Dis. 2019 09 13; 220(8):1240-1242.
    View in: PubMed
    Score: 0.467
  7. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
    View in: PubMed
    Score: 0.463
  8. Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
    View in: PubMed
    Score: 0.458
  9. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 12 18; 36(52):8054-8061.
    View in: PubMed
    Score: 0.441
  10. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
    View in: PubMed
    Score: 0.360
  11. Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016 Apr 15; 213(8):1211-3.
    View in: PubMed
    Score: 0.357
  12. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
    View in: PubMed
    Score: 0.340
  13. Influenza A(H5N1) vaccines: are we better prepared for the next pandemic? J Infect Dis. 2014 Jan 01; 209(1):1-3.
    View in: PubMed
    Score: 0.311
  14. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.286
  15. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
    View in: PubMed
    Score: 0.275
  16. Intanza(?): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010 Dec; 9(12):1399-409.
    View in: PubMed
    Score: 0.254
  17. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.237
  18. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11; 28(2):379-85.
    View in: PubMed
    Score: 0.236
  19. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010 Jan 08; 28(3):840-8.
    View in: PubMed
    Score: 0.235
  20. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
    View in: PubMed
    Score: 0.226
  21. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323-44.
    View in: PubMed
    Score: 0.223
  22. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol. 2009; 333:431-51.
    View in: PubMed
    Score: 0.223
  23. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
    View in: PubMed
    Score: 0.220
  24. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
    View in: PubMed
    Score: 0.219
  25. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008 Aug; 7(6):713-9.
    View in: PubMed
    Score: 0.216
  26. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7.
    View in: PubMed
    Score: 0.210
  27. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol. 2007 Oct; 7(5):484-90.
    View in: PubMed
    Score: 0.201
  28. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
    View in: PubMed
    Score: 0.186
  29. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.162
  30. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 08 11; 228(3):287-298.
    View in: PubMed
    Score: 0.153
  31. Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy. Semin Pediatr Infect Dis. 2002 Apr; 13(2):112-9.
    View in: PubMed
    Score: 0.139
  32. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis. 2001 Jan 15; 183(2):329-332.
    View in: PubMed
    Score: 0.127
  33. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.113
  34. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
    View in: PubMed
    Score: 0.100
  35. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
    View in: PubMed
    Score: 0.095
  36. Challenges Remain for Influenza Vaccination of Children. J Infect Dis. 2016 11 15; 214(10):1470-1472.
    View in: PubMed
    Score: 0.095
  37. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine. 2016 07 19; 34(33):3796-802.
    View in: PubMed
    Score: 0.093
  38. Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
    View in: PubMed
    Score: 0.090
  39. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.088
  40. Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
    View in: PubMed
    Score: 0.085
  41. Diurnal variation in responses to influenza vaccine. Chronobiol Int. 1995 Feb; 12(1):28-36.
    View in: PubMed
    Score: 0.085
  42. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.084
  43. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
    View in: PubMed
    Score: 0.083
  44. Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans. J Infect Dis. 1994 Feb; 169(2):477.
    View in: PubMed
    Score: 0.079
  45. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993 Feb; 167(2):305-11.
    View in: PubMed
    Score: 0.074
  46. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993; 11(9):909-13.
    View in: PubMed
    Score: 0.073
  47. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine. 2012 Dec 17; 31(1):190-5.
    View in: PubMed
    Score: 0.073
  48. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011 Sep 15; 204(6):854-63.
    View in: PubMed
    Score: 0.067
  49. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.067
  50. Antibody quantity versus quality after influenza vaccination. Vaccine. 2009 Oct 23; 27(45):6358-62.
    View in: PubMed
    Score: 0.059
  51. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
    View in: PubMed
    Score: 0.058
  52. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
    View in: PubMed
    Score: 0.058
  53. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
    View in: PubMed
    Score: 0.055
  54. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29; 26(32):4057-61.
    View in: PubMed
    Score: 0.053
  55. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
    View in: PubMed
    Score: 0.052
  56. Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007 Jul; 1(4):147-56.
    View in: PubMed
    Score: 0.050
  57. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
    View in: PubMed
    Score: 0.050
  58. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.048
  59. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005 Nov-Dec; 1(6):239-44.
    View in: PubMed
    Score: 0.045
  60. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005 Feb 03; 23(11):1414-25.
    View in: PubMed
    Score: 0.042
  61. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002 Jan 15; 20(7-8):1099-105.
    View in: PubMed
    Score: 0.034
  62. Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997 Aug; 176 Suppl 1:S38-44.
    View in: PubMed
    Score: 0.025
  63. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis. 1996 Feb; 173(2):453-6.
    View in: PubMed
    Score: 0.023
  64. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine. 1995 Dec; 13(18):1799-803.
    View in: PubMed
    Score: 0.022
  65. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
    View in: PubMed
    Score: 0.022
  66. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine. 1990 Jun; 8(3):217-24.
    View in: PubMed
    Score: 0.015
  67. Influenza: its control in persons and populations. J Infect Dis. 1986 Mar; 153(3):431-40.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.